Boone v. Boehringer Ingelheim Pharmaceuticals, Inc.

Summary

The court affirmed the judgment for the defendants after rejecting four challenges to the trial court's rulings. It held that the plaintiff could not challenge restrictions on spoliation evidence after inducing the court to use an adverse-inference instruction instead, that the excluded deposition excerpt was not proper rebuttal, that the reversal-agent design-defect claim was preempted because federal approval was required, and that the curative instruction concerning a preempted failure-to-test claim was not reversible error.